ERBB2 and triple-negative breast carcinoma: NCT offers significant benefits, particularly in patients with HER2-positive and triple-negative breast cancer (TNBC), achieving a pCR rate of 50%-60% (31–33) and correlating with favorable long-term survival outcomes in populations that attain pCR (34, 35).